Abstract Although prostate cancer is the most commonly diagnosed cancer among men in developed populations, recent recommendations against routine prostate-specific antigen screening have cast doubt on its utility for early detection. We compared the metabolomic profiles of prospectively collected fasting serum from 74 prostate cancer cases and 74 controls selected from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort of male smokers. Circulating 1-stearoylglycerol (1-SG, or 1-monostearin) was statistically significantly inversely associated with risk of prostate cancer after Bonferroni correction for multiple comparisons (i.e., 420 identified metabolites) (OR 0.34, 95 % CI 0.20-0.58, p 6.3 9 10 -5 ). The magnitude of this association did not differ by disease aggressiveness and was observed for cases diagnosed up to 23 years after blood collection. Similar but somewhat weaker prostate cancer risk signals were also evident for glycerol and alpha-ketoglutarate. In this population, men with higher serum 1-SG were less likely to develop prostate cancer, supporting a role for dysregulation of lipid metabolism in this malignancy. Additional studies are needed to retest the association and to examine 1-SG for its potential as a prostate cancer early detection marker.
Introduction
Although prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer death in most developed populations, there are no well-established modifiable risk factors for the disease (Brawley 2012) . Further, several organizations have recommended against routine prostate-specific antigen (PSA) screening, the one available early detection marker, because of over-diagnosis and over-treatment (Moyer and Force 2012) . Emerging metabolomic technologies that measure an array of low molecular weight biochemicals in blood and other tissue have the potential to identify compounds relevant to cancer etiology and early detection (Nicholson and Lindon 2008; O'Connell 2012) . As recently reviewed, a few studies have compared the metabolomic profiles of prostate tissue, urine, or blood from men with and without prostate cancer, and by disease aggressiveness (Trock 2011) , and another study specifically compared the plasma metabolomic profiles of men with stage 2 prostate cancer to those of healthy volunteers (Lokhov et al. 2010 ). To our knowledge, however, no studies to date have examined pre-diagnostic metabolomic profiles in circulation years in advance of disease in relation to subsequent risk of prostate cancer. We report here discovery within a prospective nested casecontrol study of a novel metabolite associated with prostate cancer up to two decades prior to diagnosis.
Materials and methods
Details of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study have been described (1994) . Briefly, 29,133 Caucasian male smokers from southwestern Finland were recruited between 1985 and 1988. Men were between 50 and 69 years old at baseline and smoked at least 5 cigarettes per day, as part of the study eligibility criteria. Men who were enrolled in the trial were assigned to one of four intervention groups based on a 292 factorial design: 1) a-tocopherol (dl-a-tocopheryl-acetate, 50 mg/ day), 2) b-carotene (20 mg/day), 3) both supplements, or 4) placebo. Trial participants took the study capsules for 5-8 years (median 6.1 years), until death, or until the trial ended on April 30, 1993. At enrollment, participants completed questionnaires about general risk factors, smoking, and medical history as well as a validated foodfrequency questionnaire, and had their height and weight measured and an overnight fasting serum sample collected (protected from light and stored at -70°C until assayed). Written informed consent was obtained from all participants, and the trial was approved by institutional review boards at both the Finnish National Public Health Institute and the US National Cancer Institute.
The present analysis includes 74 confirmed cases of incident prostate adenocarcinoma diagnosed from 1 to 23 years after blood collection matched 1:1 with controls on age (±1 year) and date of baseline blood collection (±30 days). Aggressive cases were over-sampled (n = 53) to permit their examination separately and defined as TNM stage III-IV, AJCC stage C3, or Gleason grade C8 (Gleason data available for all but one case). Serum metabolomic profiling was conducted at Metabolon, Inc. (Durham, NC) using ultrahigh performance liquid chromatography/mass spectroscopy (LC-MS) and gas chromatography/mass spectroscopy (GC-MS). Raw data were extracted, peak-identified, and quality control (QC) processed on the assay platform as previously described (Dehaven et al. 2010; Evans et al. 2009 ). After excluding 206 metabolites not detected in all batches, there were 420 identified compounds for analysis. Each batch included blinded duplicate QC samples. The median and interquartile range of the intraclass correlation coefficients (ICC) across the metabolites was 0.84 (0.57-0.95). These ICCs are similar to those previously observed for blood samples analyzed by the same laboratory (Sampson 2013) . Serum total PSA concentration was measured for 122 of the participants in this study in the laboratory of Dr. Alan Remaley in the NIH Clinical Center. Each batch included blinded duplicate QC samples, with the CVs ranging from 5 to 10 %.
For each metabolite and subject, signal strength was divided by the batch median value to standardize for batch variability; these normalized levels were then log-transformed and missing values were assigned the minimum non-missing value. We estimated the association between log-metabolite levels and prostate cancer by unmatched logistic regression; results from matched analyses were very similar. Multivariable models were adjusted for age, batch, trial supplement assignment, first-degree family history of prostate cancer, and physical activity. We also examined height, body mass index, smoking, education, intakes of total energy, fruit, vegetables, red meat, alcohol, and caffeine, and use of supplements, but they were not associated with prostate cancer (all p C 0.16, Table 1 ) and were not included in the model. A threshold for statistical significance of 0.000119 was applied based on a Values are means unless otherwise indicated. All characteristics are from the baseline questionnaire except family history which was collected during follow-up and is available for 107 men in this study 1-Stearoylglycerol and risk of prostate cancer 1037 Bonferroni correction for 420 tests. It should be noted that this is a highly conservative (i.e., stringent) threshold because of intercorrelation between several metabolites. All analyses were performed using SAS version 9.1.3 (SAS Institute, Cary, NC), and all statistical tests were 2-sided.
Results
Characteristics of the study population by case status are shown in Table 1 . No factors appeared to differ by case status, with the possible exception of lower physical activity among the cases. The top twenty metabolites associated with overall, nonaggressive, and aggressive prostate cancer after multivariable adjustment are shown in Table 2 (results for all identified metabolites are presented in Online Resource 1). We found that 1-stearoylglycerol (1-SG, or 1-monostearin) was statistically significantly inversely associated with risk of overall prostate cancer, and the magnitude of this association did not differ appreciably by disease aggressiveness ( Table 2 ). The ICC for 1-SG was 0.77. An inverse association with the related compound glycerol was also observed, although it was not statistically significant after correction for multiple comparisons. The association between 1-SG and risk of prostate cancer persisted and was more highly ranked among cases diagnosed [5 years after blood collection (OR 0.20, 95 % CI 0.07-0.57, p = 0.0024). Further adjustment for serum total cholesterol did not alter our findings (data not shown). Another highly ranked metabolite in our analysis was alpha-ketoglutarate (Table 2) , along with an unnamed compound that could not be definitively structurally elucidated but appeared related to alpha-ketoglutarate (OR 0.49, 95 % CI 0.33-0.72, p = 0.0003). None of these compounds were strongly correlated with serum total PSA concentration (1-SG: r = -0.15, p = 0.10; glycerol: r = 0.01, p = 0.93; alphaketoglutarate: r = -0.16, p = 0.08).
Discussion
1-SG is a monoacylglycerol, a class of compounds that can be products of lipid catabolism and converted to free fatty acids by monoacylglycerol lipase (MAGL). A recent study found markedly lower expression of 1-SG in two subtypes of hepatocellular carcinoma tumor versus adjacent normal tissue (Beyoglu et al. 2013) , suggesting that lipid catabolism is an important feature of these tumor subtypes. This is consistent with the known reprogramming of lipid biosynthetic pathways in cancer cells that provides energy and metabolites to facilitate growth, proliferation and progression (Menendez 2010) . Recent studies have also demonstrated a role for MAGL in cancer pathogenesis and, in particular, in prostate cancer aggressiveness, with greater MAGL expression in more aggressive cell lines (e.g., SKOV3, C8161, 231MFP, PC3, and DU145), and attenuation of aggressive characteristics by pharmacological disruption of, or through RNA-interference with, its activity (Nomura et al. 2010 (Nomura et al. , 2011 . Our observation of lower 1-SG concentrations in pre-diagnostic serum of men with prostate cancer relative to controls is consistent with such changes in tumor metabolism; further research will be required to determine whether this finding is specific to prostate cancer or to carcinogenesis more generally. Although the three prior prostate cancer-circulating metabolite analyses did not find a similar association for 1-SG, none of these studies reported 1-SG among their identified metabolites and none were prospective, with blood collected and stored years in advance of the diagnosis of cancer (Lokhov et al. 2010; Sreekumar et al. 2009; Thysell et al. 2010) . Also, we and others were not able to replicate the findings of these previous studies; for example, the tumor tissue sarcosine finding of an early study (Sreekumar et al. 2009) , and the significant associations with good predictive values for two metabolites, acylcarnitine and arachidonoyl amine (Lokhov et al. 2010 ), which were not identified by our LC-MS/GC-MS metabolomic platform. Differences across studies such as those resulting from case selection (e.g., stage of disease), biospecimens (e.g., plasma or tumor tissue, and preparation), temporality (i.e., when samples are collected relative to diagnosis), and a wide range of metabolomic platforms and identifiable molecular species make cross-study comparisons challenging. The inherently dynamic nature of the human metabolome likely also plays a role. A strength of the present study was the use of fasting serum specimens that were collected up to 20 years in advance of prostate cancer diagnoses and excellent laboratory quality control as indicated by ICCs; yet, based on the parent study, we were only able to examine smokers which will require broadening in future studies.
Concluding remarks
In this study of smokers, we found 1-SG to be inversely associated with risk of prostate cancer up to 23 years prior to diagnosis, supporting a role for dysregulation of lipid metabolism in prostate carcinogenesis. Further studies are needed to reexamine our findings, including particularly whether the 1-SG metabolite signal strength varies during a 10 or 20 year sub-clinical, prediagnostic period and may have potential utility as an early detection biomarker. Studies with serial blood sampling prior to diagnosis will be very informative in this regard. Whether the observed prostate cancer signal for 1-SG is independent of PSA concentrations should also be examined further.
